List view / Grid view
Researchers have developed a test that accurately predicts whether patients with ALK-positive lung cancer will respond to targeted treatments. This could significantly enhance personalised cancer therapies and overcome treatment resistance.
Discover how Immorta Bio's cellular therapies are addressing cancer and liver failure, with the potential to transform healthcare.
Explore how FDA’s Project Optimus is reshaping oncology drug dosing strategies, with insights on precision medicine, adaptive trial designs, and the role of CROs in optimising patient outcomes.
Recent advancements in targeted therapies and immunotherapies are transforming lung cancer treatment. Discover how these innovations are improving outcomes and providing hope for patients.
Insilico Medicine’s AI-designed drug ISM5939 has received FDA IND clearance for treating solid tumours. By targeting ENPP1, it enhances anti-tumour immunity and is set to begin Phase I trials soon.
The newly identified KRAS G12C inhibitor, with SHP2 inhibition, sensitises tumours to immune checkpoint blockade.
A human pancreatic cancer fibrotic barrier model illuminates how targeting the TGFβ/ROCK2/YAP signalling axis could enhance drug delivery.
Through multi-omics analysis, researchers find that oestrogen signalling could be a target for never-smoker lung cancer cases.
In this Q&A, Ichan Mount Siani researchers Dr Diego Chowell and Dr Robert Samstein share their new insights about the associations between human leukocyte antigen (HLA) class II loci and lung cancer risk.
A highly specific blood test can differentiate between patients with sarcoidosis and other respiratory conditions, like TB or lung cancer.
The first complete control map for any protein has been made for KRAS, and four potential drug targets have been discovered.
New findings about how RBM10 inhibits lung cancer growth offers potential for an anti-cancer drug and more personalised treatment.
New understanding of how lung cancer cells become more aggressive when nutrient deprived could lead to novel combination treatments.
Lactate producing bacteria is responsible for rewiring metabolic signalling pathways, causing resistance to radiation therapy.
US study uncovers the best way to treat recurrent or progressive brain metastases using an amino acid PET technique.
